Additionally, EphA3, often overexpressed in hematologic malignancies, has been targeted by the humaneered derivative of the IIIA4 anti-EphA3 mAb (KB004) in clinical trials for hematological malignancies. Here, EPHA3 is linked to hematologic disorder.